Amgen, Inc. (NASDAQ:AMGN)

research

Amgen Earnings Point to New 52-Week High

Amgen Corp. (NASDAQ: AMGN) reported fiscal second quarter 2015 earnings Thursday afternoon after equity markets had closed. The biotech firm posted adjusted earnings per share (EPS) of $2.57 on revenues ...
Read Full Story »
biotech

What to Expect from Amgen Earnings

Amgen Inc. (NASDAQ: AMGN) is scheduled to report its earnings after the markets close on Thursday. There are consensus estimates from Thomson Reuters that call for $2.43 in earnings per ...
Read Full Story »
biotech

Short Sellers Back Off Major Biotechs

The short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

Pharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc. ...
Read Full Story »
amgnlogo

4 Large Cap Biotech Stocks to Buy Before Earnings

The biotech industry has been on an outstanding run over the past year, and some top analysts on Wall Street think that run could be poised to continue. A new ...
Read Full Story »
Biotechnology word cloud

Short Sellers Back Off Big Biotech

The short interest data are out for the June 30 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
investing

4 Defensive Stocks to Buy Now for Continued Market Volatility

While Thursday's rally was a very welcome sight, and Friday could be even better, the problems that were shaking the market are still looming right in the background. With no ...
Read Full Story »
fda_logo

5 Big Upcoming FDA Decisions Expected in July

Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, similar to that ...
Read Full Story »
DNA

Short Sellers Get More Selective on Big Biotech

The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Biotechnology word cloud

Short Sellers Lose Some Conviction Against Big Biotech

The short interest data are out for the May 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
145922793

New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels

This coming week is likely to be a serious one in the fight against cholesterol. This covers a new class of drugs in the PCSK9 classification, and FDA panels are ...
Read Full Story »
Biotechnology word cloud

Short Sellers Get Even More Ambitious Against Biotech Leaders

The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech

The Most Loved Biotechs of Big Hedge Funds

With such a mixed performance over the past decade, some of us wonder why hedge funds are so revered. Ditto for many of the so-called guru fund managers. Still, investors ...
Read Full Story »
biotech

Short Sellers Start to Get Nervous on Biotech

The short interest data are out for the April 30 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Biotechnology word cloud

Short Sellers Become More Wary of Big Biotech

The short interest data are out for the April 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »